Abstract

Case Study

Male in Early Adolescence Presenting with Guillain-Barré Syndrome Following BECOV2D Vaccine

Vinit Suri*, Kanika Suri, Kunal Suri and Priyal

Published: 07 August, 2023 | Volume 7 - Issue 1 | Pages: 001-004

COVID vaccination has been associated with serious disorders including thrombosis with thrombocytopenia syndrome (TTS), Guillain-Barré syndrome (GBS), and myocarditis. GBS has been reported in adults following COVID-19 infection and rarely following the COVID-19 vaccination. Post COVID vaccination GBS has been associated with prominent and early facial diplegia and quadriplegia. Extension of the COVID vaccination program to the pediatric age group of 5 to 17 years has exposed this population to the adverse effects of the vaccination. Only a few case reports of post-vaccination GBS have been reported in the pediatric age group without any data on the true prevalence. We report a case of a male in his early adolescence with GBS presenting as facial diplegia and rapid quadriplegia following the BECOV2D, (Corbevax) vaccination. Our case is the first case of GBS reported following BECOV2D, (Corbevax) vaccination and highlights the presentation with prominent and early diplegia, which is similar to the presentation in adults.

Read Full Article HTML DOI: 10.29328/journal.jcavi.1001010 Cite this Article Read Full Article PDF

Keywords:

Corbevax; Pediatric; Guillain-Barré syndrome; Post-vaccination GBS

References

  1. MacNeil JR, Su JR, Broder KR, Guh AY, Gargano JW, Wallace M, Hadler SC, Scobie HM, Blain AE, Moulia D, Daley MF, McNally VV, Romero JR, Talbot HK, Lee GM, Bell BP, Oliver SE. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):651-656. doi: 10.15585/mmwr.mm7017e4. PMID: 33914723; PMCID: PMC8084127.
  2. Woo EJ, Mba-Jonas A, Dimova RB, Alimchandani M, Zinderman CE, Nair N. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. JAMA. 2021 Oct 26;326(16):1606-1613. doi: 10.1001/jama.2021.16496. PMID: 34617967; PMCID: PMC8498927.
  3. Salah HM, Mehta JL. COVID-19 Vaccine and Myocarditis. Am J Cardiol. 2021 Oct 15;157:146-148. doi: 10.1016/j.amjcard.2021.07.009. Epub 2021 Jul 12. PMID: 34399967; PMCID: PMC8272967.
  4. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barré Syndrome (GBS) following adenovirus vector COVID-19 vaccines.The statement, 26 July 2021 
  5. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020 May;19(5):383-384. doi: 10.1016/S1474-4422(20)30109-5. Epub 2020 Apr 1. PMID: 32246917; PMCID: PMC7176927.
  6. Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021 Apr;268(4):1133-1170. doi: 10.1007/s00415-020-10124-x. Epub 2020 Aug 25. PMID: 32840686; PMCID: PMC7445716.
  7. Kim JE, Min YG, Shin JY, Kwon YN, Bae JS, Sung JJ, Hong YH. Guillain-Barré Syndrome and Variants Following COVID-19 Vaccination: Report of 13 Cases. Front Neurol. 2022 Jan 27;12:820723. doi: 10.3389/fneur.2021.820723. PMID: 35153993; PMCID: PMC8833101.
  8. Malamud E, Otallah SI, Caress JB, Lapid DJ. Guillain-Barré Syndrome After COVID-19 Vaccination in an Adolescent. Pediatr Neurol. 2022 Jan;126:9-10. doi: 10.1016/j.pediatrneurol.2021.10.003. Epub 2021 Oct 8. Erratum in: Pediatr Neurol. 2021 Dec 10;: PMID: 34717201; PMCID: PMC8498800.
  9. Kim Y, Zhu Z, Kochar P, Gavigan P, Kaur D, Kumar A. A Pediatric Case of Sensory Predominant Guillain-Barré Syndrome Following COVID-19 Vaccination. Child Neurol Open. 2022 Jan 25;9:2329048X221074549. doi: 10.1177/2329048X221074549. PMID: 35097156; PMCID: PMC8793378.
  10. Keh RYS, Scanlon S, Datta-Nemdharry P, Donegan K, Cavanagh S, Foster M, Skelland D, Palmer J, Machado PM, Keddie S, Carr AS, Lunn MP; BPNS/ABN COVID-19 Vaccine GBS Study Group. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database. Brain. 2023 Feb 13;146(2):739-748. doi: 10.1093/brain/awac067. PMID: 35180300; PMCID: PMC8903477.
  11. Lee HY, Lien WC. Effects of COVID-19 vaccine type on Guillain-Barré syndrome: Two cases and a literature review. Hum Vaccin Immunother. 2023 Dec 31;19(1):2171231. doi: 10.1080/21645515.2023.2171231. Epub 2023 Feb 22. PMID: 36919452; PMCID: PMC10026858.
  12. Woo EJ, Gee J, Marquez P, Baggs J, Abara WE, McNeil MM, Dimova RB, Su JR. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022. Vaccine. 2023 Jul 5;41(30):4422-4430. doi: 10.1016/j.vaccine.2023.06.023. Epub 2023 Jun 14. PMID: 37321898; PMCID: PMC10264169.
  13. Mohseni Afshar Z, Sharma A, Babazadeh A, Alizadeh-Khatir A, Sio TT, Taghizadeh Moghadam MA, Tavakolli Pirzaman A, Mojadad A, Hosseinzadeh R, Barary M, Ebrahimpour S. A review of the potential neurological adverse events of COVID-19 vaccines. Acta Neurol Belg. 2023 Feb;123(1):9-44. doi: 10.1007/s13760-022-02137-2. Epub 2022 Nov 16. PMID: 36385246; PMCID: PMC9668235.
  14. Abara WE, Gee J, Marquez P, Woo J, Myers TR, DeSantis A, Baumblatt JAG, Woo EJ, Thompson D, Nair N, Su JR, Shimabukuro TT, Shay DK. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States. JAMA Netw Open. 2023 Feb 1;6(2):e2253845. doi: 10.1001/jamanetworkopen.2022.53845. Erratum in: JAMA Netw Open. 2023 May 1;6(5):e2315740. PMID: 36723942; PMCID: PMC9892957.
  15. Chalela JA, Andrews C, Bashmakov A, Kapoor N, Snelgrove D. Reports of Guillain-Barre Syndrome Following COVID-19 Vaccination in the USA: An Analysis of the VAERS Database. J Clin Neurol. 2023 Mar;19(2):179-185. doi: 10.3988/jcn.2022.0237. PMID: 36854334; PMCID: PMC9982177.

Figures:

Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?